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Budesonide ameliorates lung injury
induced by large volume ventilation
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Abstract
Background: Ventilation-induced lung injury (VILI) is a health problem for patients with acute respiratory dysfunction
syndrome. The aim of this study was to investigate the effectiveness of budesonide in treating VILI.
Methods: Twenty-four rats were randomized to three groups: a ventilation group, ventilation/budesonide group, and
sham group were ventilated with 30 ml/kg tidal volume or only anesthesia for 4 hor saline or budesonide airway
instillation immediately after ventilation. The PaO2/FiO2and wet-to-dry weight ratios, protein concentration, neutrophil
count, and neutrophil elastase levels in bronchoalveolar lavage fluid (BALF) and the levels of inflammation-related
factors were examined. Histological evaluation of and apoptosis measurement inthe lung were conducted.
Results: Compared with that in the ventilation group, the PaO2/FiO2 ratio was significantly increased by treatment with
budesonide. The lung wet-to-dry weight ratio, total protein, neutrophil elastase level, and neutrophilcount in BALF were
decreased in the budesonide group. The BALF and plasma tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6,
intercellular adhesion molecule (ICAM)-1, and macrophage inflammatory protein (MIP)-2 levels were decreased,
whereas the IL-10 level was increased in the budesonide group. The phosphorylated nuclear factor (NF)-kBlevels
in lung tissue were inhibited by budesonide. The histological changes in the lung and apoptosis were reduced
by budesonide treatment. Bax, caspase-3, and cleaved caspase-3 were down-regulated, and Bcl-2 was up-regulated by
budesonide.
Conclusions: Budesonide ameliorated lung injury induced by large volume ventilation, likely by improving epithelial
permeability, decreasing edema, inhibiting local and systemic inflammation, and reducing apoptosis in VILI.
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Background
Mechanical ventilation (MV) is indispensable for pa-
tients with acute respiratory distress syndrome (ARDS),
and it is required for about 39 % patients in intensive
care units [1]. However, MV can damage injured lungs
in patients with ARDS [2]. Studies have shown that
about 24 % of ARDS patients treated with MV devel-
oped ventilator-induced lung injury (VILI) [3], which
resulted in a 40–50 % mortality rate [4]. MV with a large
volume may lead to alveolar overstretching, increase
alveolar-capillary permeability, and cause pulmonary
edema [5] and lung focal inflammation [6]. Small tidal
volume MV can reduce the lung injury and lower the
mortality of ARDS [4]; however, ARDS remains a major
problem still associated witha mortality of 25–45 % in
intensive care units [7]. Therefore, it is imperative to de-
velop alternative therapies to attenuate VILI.
Studies have shown that the imbalance of pro- and
anti-inflammatory cytokines plays a critical role in the
pathogenesis of VILI [8, 9]. During VILI, cytokines are
released, leucocytes are recruited to the lung, and lung
permeability is increased, resulting in lung edema and
deterioration of pulmonary gas exchange [10]. Moreover,
the cytokines released from injured endothelial and epi-
thelial can enter the blood and cause systemic inflamma-
tion and injury to other organs.
Glucocorticoids can ameliorate the VILI [11, 12]. How-
ever, the systemic use of glucocorticoids may cause im-
munosuppression and steroid resistance [13]. In addition,
systemic use of glucocorticoids was not found toimprove
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the outcome of ARDS, butinstead led to neuromuscular
weakness and increased mortality risk for patients with
ARDS [14]. In contrast, administration of glucocorticoids
through inhalation relieves symptoms with less clinical
side effects. We also found that budesonide can ameliorate
the lung injury induced by one-lung ventilation or endo-
toxin in our clinical work and experiments [15, 16]. Other
studies also have shown that budesonide can attenuate
lung injury induced by chlorine gas, surfactant-depletion,
or aspiration [17–20]. Therefore, we hypothesized that
budesonide can reduce the incidence of VILI. In this
study, we investigated the effect of budesonide on VILI
using a rat model. Our data indicated that budesonide




All Wistar male rats were fasted and provided with water
ad libitum for 24 h before the study. Twenty-four rats were
randomized to three groups: a sham group (S), a ventila-
tion group (V), and a ventilation/budesonide group (VB)
(n = 8 per group). Rats in the V and VB groups were venti-
lated for 4 h with tidal volume 30 ml/kg [21, 22] (respira-
tory rate: 50/min, inspiratory expiratory ratio: 1:1). All rats
were anesthetized using 3 % pentobarbital sodium (30 mg/
kg intraperitoneally). The S group only received anesthesia.
A tracheotomy was performed for rats in the V and VB
groups. The caudal vein and artery were cannulated to col-
lect blood, analyze blood gas, and perform injection. After
injection of rocuronium (0.6 mg/kg), the rats in the V and
VB groups received saline or budesonide 1 mg/kg by air-
way instillation immediately after ventilation. All the
rats were maintained under anesthesia with 3 % pento-
barbital sodium (10 mg/kg) and rocuronium (0.6 mg/
kg) for a 1-h interval. The arterial blood analyses were
performed, and the peripheral blood samples were col-
lected at baseline (immediately after ventilation), 1, 2,
and 4 h after ventilation (T0-T3). After ventilation for
4 h, all the rats were sacrificed after anesthesia, and the
lungs were collected for further analysis.
Arterial blood gas analysis
The arterial blood gases from T0 to T3 were analyzed
using a Bayer Rapidlab 348 (Bayer Diognostics, Germany).
PaO2/FiO2 ratios were calculated.
Pulmonary alveolocapillary permeability
After ventilation for 4 h, the right upper lungs were
weighed and then dried at 60 °C for 48 h. The ratio of
wet/dry weight (W/D) was calculated.
Preparation of bronchoalveolar lavage fluid (BALF)
BALF was collected from the left lung by infusing chilled
saline (4 °C, 15 ml/kg) containing (EDTA)-2Na and with-
drawal five times. Cell differentiation was determined by
staining using a cytocentrifuged spin preparation (CF-RD,
Sakura, Tokyo, Japan) of the BALF. The BALF was centri-
fuged at 1000 g at 4 °C for 15 min. After centrifugation,
the BALF were immediately stored at -80 °C. The neutro-
phil levels in the BALF were counted with a cell counter.
Histopathologic analysis of lung tissue
The right lower lung was fixed with 10 % formalin, em-
bedded in paraffin, and cut into 4-μm sections. The
sections were stained with hematoxylin and eosin. Two
independent pathologists analyzed and scored the lung
injury under light microscopy from 0 to 4 (0, minimum
damage; 1, mild damage; 2, moderate damage; 3, severe
damage; and 4, maximum damage), according to the as-
sessment of alveolar congestion, edema, neutrophil in-
filtration in the airspace or vessel wall, hemorrhage, the
thickness of the alveolar wall, and hyaline membrane
formation.
Fig. 1 The effect of budesonide on wet/dry weight ratio, protein concentration, and PaO2/FiO2 in VILI. *P < 0.05, compared with the S group;
#P < 0.05, compared with the V group. ( , S group; , V group; , VB group)
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Fig. 2 The effect of budesonide onneutrophil counts and neutrophil elastase levels in the BALF in VILI. *P < 0.05, compared with the S group;
#P < 0.05, compared with the V group
Fig. 3 The effect of budesonide on TNF-α, IL-1β, IL-6, IL-10, ICAM-1, and MIP-2 levels in the BALF in VILI. *P < 0.05, compared with the S group;
#P < 0.05, compared with the V group. ( , S group; , V group; , VB group)
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TUNEL staining of lung sections
A lobe of each right lung was examined for apoptosis using
TUNEL staining with an Apoptosis Assay kit (Roche Diag-
nostics GmbH, Science, Mannheim, Germany). The slides
were incubated with proteinase Kfor 30 min and rinsed
twice with phosphate-buffered saline (PBS). Then they
were immersed in TUNEL reaction mixture at 37 °C for
60 min. After washing with PBS three times, the endogen-
ous peroxidase activity was quenched with 0.3 % H2O2
and covered with extra-avidin peroxidase, followed by
immersion in adiaminobenzidine solution. The slides
were counterstained with Mayer-hematoxylin, dehy-
drated, and mounted. The cells showing brownish
staining in the nuclei were judged as apoptotic. Ten im-
ages were randomly selected from each section, and at
least 1,000 cells were counted to calculate the apoptosis
index by independent pathologists.
Western blotting
The soluble protein was extracted from right lung tissue
using lysis buffer containing protein inhibitors (Beyotime
Biotechnology, Jiangsu, China). The concentration of the
sample protein was determined using the Bradford assay.
Aliquots of homogenate protein were resolved in polyacryl-
amide gels and transferred onto polyvinylidene fluoride
membranes. The membranes were blocked with 5 % dry
milk and then probed with antibodies for Bax, Bcl-2,
caspase-3, phosphorylated NF-kB (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), and cleaved caspase-3 (Sigma-
Aldrich, St. Louis, Missouri, USA), followed by incubation
with horseradish peroxidase-linked secondary antibodies
(Santa Cruz Biotechnology). The bands were visualized via
enhanced chemiluminescence.
Statistical analysis
All normally distributed data are presented as mean and
standard deviation (SD) and were analyzed using SPSS
11.0 (SPSS, Chicago, IL, USA). The normally distributed
data were analyzedusing the unpaired t test for a single
time-point or repeated measures analysis of variance.
The non-normally distributed data were analyzed using
Mann-Whitney rank sum test, and histologic data were
analyzed using the Wilcoxon U-test.
Results
Budesonide improves alveolocapillary permeability and
the W/D weight ratio and total protein in BALF in VILI
We evaluated the effect of budesonide on alveolocapillary
permeability in VILI. The results showed that the oxygen
index was significantly decreased after large volume
Fig. 4 Theeffect of budesonide on TNF-α, IL-1β, IL-6, IL-10, ICAM-1, and MIP-2 levels in the plasma in VILI. *P < 0.05, compared with the S group;
#P < 0.05, compared with the V group
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ventilation, compared with that in the S group. Budeso-
nide dramatically increased the oxygen index in the VB
group (Fig. 1). The W/D weight ratio and total protein in
BALF were significantly greater in the V and VB groups,
compared to the S group, but were significantly less in the
VB group compared to the V group (Fig. 1). These results
suggested that budesonide improved alveolocapillary per-
meability and the W/D weight ratio and total protein in
BALF in VILI.
Budesonide inhibits inflammation in VILI
We evaluated the effect of budesonide on inflammatio-
nin VILI. The results showed that the levels of neutro-
phils in BALF were higher in the V and VB groups than
inthe S group, but were significantly lower in the VB
group compared to theV group (Fig. 2). In addition, the
concentration of neutrophil elastase was significantly
greater in the V and VB groups compared to the S group
and lower in the VB group than in the V group (Fig. 2).
The BALF and plasma TNF-α, IL-1β, IL-6, ICAM-1, and
MIP-2 levels were significantly higher in the V and VB
group than in theS group. Compared to the V group, the
BALF and plasma TNF-α, IL-1β,IL-6, ICAM-1, and
MIP-2 levels were significantly lower, but the IL-10
level was significantly higher in the VB group (Figs. 3
and 4). In addition, phosphorylated NF-kB was signifi-
cantly up-regulated in the V and VB groups, compared
with the S group. It was down-regulated by budeso-
nide, compared with that in the VB andV groups
(Fig. 5). Taken together, these data indicate that bude-
sonide reduces local and systemic inflammation in
VILI.
Budesonide attenuates histological changes in VILI
We evaluated the effect of budesonide on histological
changes in VILI using hematoxylin and eosin (HE) stain-
ing. Under a light microscope, we observed typical VILI
pathological changes, such as severe edema, thickening of
the alveolar wall, the formation of a hyaline membrane,
hemorrhage, and neutrophil infiltration in lung paren-
chyma in the V group, but these signs of lung tissue
damage were notably reduced in the VB group (Fig. 6).
The results suggest that budesonide attenuates lung in-
jury in VILI.
Fig. 5 The effect of budesonide onthe expression of NF-kB and phosphorylated NF-kB in lung tissue in VILI. a The expression of NF-kB and
phosphorylated NF-kB in 3 groups. b The ratio of NF-kB and phosphorylated NF-kB to β-actin in 3 groups. *P < 0.05, compared with the S group;
#P < 0.05, compared with the V group
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Budesonide inhibits apoptosis in VILI
We evaluated the effect of budesonide on the apoptosis of
lung tissues in VILI using TUNEL staining and Western
blotting. We observed characteristic chromatin condensa-
tion in the nuclei of TUNEL-positive epithelial and endo-
thelial cells in the V and VB groups, but not in the S
group. These data indicated that ventilationcan induce
lung cell apoptosis (Fig. 7). The number of TUNEL-
positive cells was significantly decreased in the VB group,
compared with the V group (Fig. 7). There were apoptotic
epithelial cells, macrophages, and neutrophils in the V
group tissue sections based on changes in the nuclear
appearance and cell shape and position and less apop-
totic epithelial cells, macrophages, and neutrophils in
the VB group tissue sections (Fig. 7). The the apoptotic
rates were significantly decreased in the VB group,
compared with the V group (Epthelial: 32.8 % vs 17.6 %,
Macrophages: 18.6 % vs 8.9 %, Neutrophils: 4.4 % vs
1.5 %). In addition, the levels of Bax, Bcl-2, caspase-3,
and cleaved caspase-3 were significantly higher in the V
and VB groups than in the S group. The levels of Bax,
caspase-3, and cleaved caspase-3 were significantly
lower and the Bcl-2 level was significantly higher in the
VB group, compared to the V group (Fig. 8). Taken to-
gether, these results suggest that budesonide inhibits
apoptosis in VILI.
Discussion
MV is a life-saving treatment for patients with ARDS,
but even minimal MV can induce VILI [2]. Thus, it is
imperative to develop therapies that can attenuate VILI.
In the current study, we found that budesonide improves
alveolocapillary permeability, increases the W/D weight
ratio and total protein in BALF, inhibits inflammation,
attenuates histological changes, and inhibits apoptosis in
VILI. Our data support that budesonide may reduce the
VILI. Although several studies have indicated that bude-
sonide or systemic glucocorticoids can reduce lung in-
jury in various models and systemic glucocorticoids can
ameliorate VILI [11, 12], this is the first study to investi-
gate the effect of inhaled budesonide on VILI. VILI is a
serious and common problem in patients who need long-
term and large volume ventilation. The major injury is
found in their lungs. In this study, we administered bude-
sonide through inhalation to avoid the systemic effect of
glucocorticoids and strengthen its local efficacy.
During large volume ventilation, overstretching of epi-
thelial cells activates NF-kB and promotes NF-kB phos-
phorylation. Under stimulation of mechanical ventilation,
many chemoattractant and proinflammatory factors, in-
cluding IL-8, ICAM-1, and MIP-2, are released, and pul-
monary macrophages are activated and recruit neutrophils
[23, 24]. The activated macrophages and neutrophils
Fig. 6 Budesonide significantly decreased the injury caused by VILI. The lung tissues were analyzed using HE staining: (a, d) S group; (b, e)
V group; and (c, f) VB group. a-c, ×200; d-f, ×400
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release pro-inflammatory factors and elastase and contrib-
ute to the lung injury, leading to lung edema. In the
current study, we found that budesonide improved the
oxygen index, reduced histological injury in the lung, and
improved lung edema after large volume ventilation.
These results suggest that budesonide can protect the
alveolar-capillary barrier and inhibit local inflammation.
This protective effect of budesonide in VILI may be attrib-
uted to the immuno-regulation of budesonide.
In the current study, we found that budesonide signifi-
cantly decreased levels of ICAM-1 and MIP-2 in VILI.
ICAM-1 and MIP-2 are important adhesion molecules
for neutrophils [25, 26]. In VILI, the injured epithelia-
land endothelial cells can release ICAM-1 and MIP-2,
which recruits macrophages and causesneutrophil infil-
tration. The infiltrated macrophages and neutrophils
further secrete proinflammatory factors and elastase,
resulting in lung injury. Blockade of ICAM-1 can
Fig. 7 Budesonide significantly decreased VILI-induced apoptosis in lung tissues. Apoptosis among lung tissue cells was identified using TUNEL
staining. Representative images of TUNEL staining of lung tissues in the S group (a), V group (b), and VB group (c). A-C:×400. (d) The apoptosis
index in the three groups
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dramatically decrease the neutrophil influx [27] and
ameliorate lung injury [28]. Therefore, budesonide likely
reduced VILI by protecting the epithelial and endothelial
cells from injury.
We also found that budesonide decreased the TNF-α, IL-
1β, IL-6, and elastase levels and increased the IL-10 level in
VILI. These results are consistent with those of previous stud-
ies [16, 29]. It has been shown that TNF-α and IL-1β are sig-
nificantly elevated and play pivotal roles during the
pathogenesis of VILI [30]. TNF-α,IL-1β, IL-6, and elastase are
important proinflammatory factors thatnot only directly in-
jure the lung tissue but also contribute to the aggravation of
inflammation and induce cell apoptosis. IL-10 can antagonize
the effect of TNF-α, IL-1β, and IL-6, and inhibit inflammatory
cell migration [31]. Therefore, the budesonide-based reduc-
tion in VILI is achieved likely by regulating pro- and anti- in-
flammatory factors to reduce inflammation.
NF-kB is a transcription factor and a master regulator of
the expression of the pro- and anti- inflammatory factors
[20]. Activation of NF-kB by phosphorylation plays a
pivotal role in cytokine regulation and inflammation. In-
hibition of NF-kB activation can significantly decrease ALI
[23, 32]. In the current study, we found that phosphorylated
NF-kB were significantly up-regulated after ventilation, but
dramatically down-regulated by budesonide. These data
suggest that NF-kB is activated by large volume ventilation
and this activation is inhibited by budesonide. Budesonide
regulate the levels of pro- and anti-inflammatory cytokines
probably by inhibiting activation of NF-kB.
In the current study, we also detected elevated levels of
TNF-α, IL-1β, and IL-6 in the peripheral blood of rats with
VILI, suggesting that the inflammation induced by VILI is
not restricted to the lung and may spread to extrapulmon-
ary organs and lead to a systemic inflammatory response
and extrapulmonary organ dysfunction. This is consistent
with the findings of a previous study [33]. The peripheral
blood TNF-α, IL-1β, and IL-6 levels in rats with VILI were
decreased after budesonide treatment. Thus, it is likely that
budesonide may also reduce systemic inflammation.
Apoptosis plays a key role in VILI [22, 34]. In this study,
we found apoptosis in the cells of lung tissue and this was
significantly decreased by budesonide. This is consistent
with previous studies that showed budesonide can inhibit
apoptosis [35, 36] via inhibition of p38 MAPK phosphoryl-
ation [36]. Further, we found that the Bax, caspase-3, and
cleaved caspase-3 levels were increased in VILI and the
Bcl-2 level was down-regulated, but reversed to certain
levels with budesonide treatment. Bax is a pro-apoptotic
protein and a major regulatory checkpoint for apoptosis
[37]. In contrast, Bcl-2 is an anti-apoptotic protein that
can prevent activation of Bax. The ratio of Bax and Bcl-2
played a key role in the protection against or acceleration
of apoptosis. Cleaved caspase-3 is the executor protein of
apoptosis, will cut the DNA, and promote cell apoptosis.
Both intrinsic and extrinsic pathways can activate caspase-
3 and generate the cleaved caspase-3. Therefore, budeso-
nide reduced apoptosis likely by regulating the expression
of Bax and Bcl-2. In addition, we also found that
Fig. 8 The effect of budesonide onBax, Bcl-2, caspase-3 and cleaved caspase-3 levels in VILI. a The Bax, Bcl-2, caspase-3 and cleaved caspase-3
levels in lung tissues were determined using Western blotting. b Densitometry analysis of the data shown in a
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macropahges and neutrophils underwent apoptosis. Dur-
ing VILI, the macrophages and neutrophils were activated
and phagocytized the necrotic cells and then underwent
apoptosis. However, in this study, we only compared the
apoptosis of epithelial cells to evaluate the effect of bude-
sonide on VILI. We can differentiate the macrophages and
neutrophils from epithelial cells based on the position,
shape, and nuclear characteristics of these cells.
This study has several limitations. First, rats were venti-
lated with a tidal volume of 30 ml/kg, which is substan-
tially higher than volumes used in clinical application. Our
preliminary study showed that a lower tidal volume (10–
15 ml/kg) did not cause a decline in the PaO2/FiO2 ratio
and VILI. Therefore, we increased the tidal volume to
30 ml/kg, and we successfully established the signifi-
cantly decreased PaO2/FiO2and mild acute respiratory
distress syndrome. Therefore, we used the tidal volume
of 30 ml/kg to establish VILI. This is consistent with
the study by Li et al whoalso used the 30 ml/kg tidal
volume to induce ALI [21, 22]. Second, in this study,
budesonide was administered at the onset of VILI, sup-
porting the use of budesonide as a preventative treatment.
Clinically, however, patients need mechanical ventilation
support before dysfunction of or injury to the lung occurs.
Third, we did not evaluate the purity of neutrophils in
BALF, which may influence the judgment of the effects of
budesonide on neutrophils in VILI. We will address these
limitations in our future studies.
Conclusion
In conclusion, in the current study, we found that budeso-
nide ameliorated lung injury probably by improving epi-
thelial permeability, decreasing edema, inhibiting local
and systemic inflammation, and reducing apoptosis in
VILI. We speculate that inhalation of budesonide reduces
lung injury and edema via inhibition of NF-kB phosphor-
ylation and decreased secretion of adhesion molecules
and pro-inflammatory factors, which reduceslocal and sys-
temic inflammation. Budesonide inhalation may be a po-
tential approach for ARDS therapy in clinical practice.
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